These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23248148)

  • 21. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
    Nilsson PM
    Lakartidningen; 2008 May 7-13; 105(19):1382-4. PubMed ID: 18574975
    [No Abstract]   [Full Text] [Related]  

  • 22. [Telmisartan].
    Krankenpfl J; 2005; 43(4-6):110-1. PubMed ID: 16171056
    [No Abstract]   [Full Text] [Related]  

  • 23. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
    Mancia G; Unger T; Zanchetti A
    J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A; Baliga V;
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
    MMW Fortschr Med; 2003 Dec; 145(51-52):39. PubMed ID: 14974331
    [No Abstract]   [Full Text] [Related]  

  • 26. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?
    Weber MA
    Am J Cardiol; 2002 Jan; 89(2A):27A-33A. PubMed ID: 11835909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Introduction. Telmisartan in the treatment of hypertension--addressing the early morning risk: international experiences in different populations.
    Redon J
    Int J Clin Pract Suppl; 2004 Dec; (145):1-2. PubMed ID: 15617451
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.
    Delles C; Raff U; Mimran A; Fauvel JP; Ruilope LM; Schmieder RE
    Am J Hypertens; 2008 Dec; 21(12):1330-6. PubMed ID: 18989258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ACE inhibitors in cardiovascular disease--unbeatable?
    McMurray JJ
    N Engl J Med; 2008 Apr; 358(15):1615-6. PubMed ID: 18378521
    [No Abstract]   [Full Text] [Related]  

  • 31. Renin-angiotensin blockade and kidney disease.
    Sarafidis PA; Bakris GL
    Lancet; 2008 Aug; 372(9638):511-2. PubMed ID: 18707969
    [No Abstract]   [Full Text] [Related]  

  • 32. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
    Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
    J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
    Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there room for dual blockade of the renin-angiotensin-aldosterone system?
    Hollenberg NK
    J Hypertens; 2012 Apr; 30(4):671-2. PubMed ID: 22418900
    [No Abstract]   [Full Text] [Related]  

  • 36. Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?
    Hankey GJ; ; ;
    Stroke; 2003 Feb; 34(2):354-6. PubMed ID: 12574534
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
    Burnier M; Waeber B; Hess O; Lüscher T
    Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
    [No Abstract]   [Full Text] [Related]  

  • 38. . . . and losartan was no better than placebo.
    Messerli FH
    J Hum Hypertens; 1999 Oct; 13(10):649-50. PubMed ID: 10516732
    [No Abstract]   [Full Text] [Related]  

  • 39. [These hypertensive patients are especially at risk for myocardial infarct in the morning. Screen for non-dippers].
    MMW Fortschr Med; 2002 Nov; 144(46):69. PubMed ID: 12534089
    [No Abstract]   [Full Text] [Related]  

  • 40. New clinical concepts after the ONTARGET trial.
    Ruilope LM; Segura J; Zamorano JL
    Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.